The Cooper Companies, Inc.

Valuation Analysis

About the Company

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group

The Cooper Companies, Inc. Stock at a Glance

The Cooper Companies, Inc. (COO) is currently trading at $67.88 with a market capitalization of $13.2B. The trailing P/E ratio stands at 57.53x, with a forward P/E of 13.58x. The 52-week range spans from $58.89 to $89.83; the current price is 24.4% below the yearly high. Year-over-year revenue growth stands at +7.9%. The net profit margin stands at 5.57%.

💰 Dividend

The Cooper Companies, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

14 analysts rate The Cooper Companies, Inc. (COO) on consensus: Buy. The average price target is $80.57, implying +18.7% from the current price. Analyst price targets range from $66.00 to $92.00.

The Cooper Companies, Inc.: The Investment Case in Detail

The Cooper Companies, Inc. (COO) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 65.55%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 18.7% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.68, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 13.58x is meaningfully below the trailing 57.53x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy The Cooper Companies, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.